Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.38 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | GPR39 | O43194 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2829978 | 0.98 | KDM4E (0.47) | KDM4EALDH1A1L3MBTL1GAACTSK | |
| SCHEMBL8485490 | 0.91 | ALDH1A1 (0.39) | KDM4EALDH1A1L3MBTL1GAACTSK | |
| SCHEMBL6950560 | 0.83 | HRH3 (0.49) | KDM4EALDH1A1L3MBTL1HRH4PDGFRB | |
| SCHEMBL20898821 | 0.83 | MAPK1 (0.50) | KDM4EALDH1A1L3MBTL1HRH4MKNK1 | |
| SCHEMBL20898861 | 0.81 | JAK2 (0.38) | KDM4EALDH1A1L3MBTL1CTSKMKNK1 | |
| SCHEMBL4709850 | 0.77 | NOS2 (0.40) | KDM4EALDH1A1L3MBTL1MAPT | |
| SCHEMBL4709849 | 0.77 | NOS2 (0.40) | KDM4EALDH1A1L3MBTL1MAPT | |
| SCHEMBL9901706 | 0.70 | KDM4E (0.53) | KDM4EALDH1A1L3MBTL1GAACTSK | |
| SCHEMBL30182919 | 0.70 | KDM4E (0.53) | KDM4EALDH1A1L3MBTL1GAACTSK | |
| SCHEMBL30183229 | 0.70 | KDM4E (0.53) | KDM4EALDH1A1L3MBTL1GAACTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2620150-A2 | 2-Amido Thiazole Based Inhibitors of ATP-Utilizing Enyzmes | Genentech, Inc. (US) | 2013-07-31 | — | — | EP | claimed |
| EP-2168578-A2 | 2-Amido-Thiazole-Based Compounds Exhibiting ATP-Utilizing Enzyme Inhibitory Activity, and Compositions, and Uses Thereof | Genentech, Inc. (US) | 2010-03-31 | — | — | EP | claimed |
| US-20090048313-A1 | 2-AMIDO-THIAZOLE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | GENENTECH, INC. (US) | 2009-02-19 | — | — | US | claimed |
| EP-1781287-A4 | THIAZOLE BASED INHIBITORS OF ATP-UTILIZING ENYZMES | GENENTECH INC (US) | 2008-02-27 | — | — | EP | claimed |
| EP-1781287-A2 | THIAZOLE BASED INHIBITORS OF ATP-UTILIZING ENYZMES | Genentech, Inc. (US) | 2007-05-09 | — | — | EP | claimed |
| US-20060052416-A1 | 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof | SQUARE 1 BANK | 2006-03-09 | — | — | US | claimed |
| WO-2006020767-A2 | THIAZOLE BASED INHIBITORS OF ATP-UTILIZING ENZYMES | GENENTECH, INC. (US) | 2006-02-23 | — | — | WO | claimed |
| EP-2620150-A2 | 2-Amido Thiazole Based Inhibitors of ATP-Utilizing Enyzmes | Genentech, Inc. (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-2168578-B1 | Thiazole based inhibitors of ATP-utilizing enzymes | GENENTECH INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-7795290-B2 | 2-amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof | GENENTECH, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| EP-2168578-A2 | 2-Amido-Thiazole-Based Compounds Exhibiting ATP-Utilizing Enzyme Inhibitory Activity, and Compositions, and Uses Thereof | Genentech, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090048313-A1 | 2-AMIDO-THIAZOLE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | GENENTECH, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-7410988-B2 | 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof | GENENTECH, INC. (US) | 2008-08-12 | — | — | US | disclosed |
| EP-1781287-A4 | THIAZOLE BASED INHIBITORS OF ATP-UTILIZING ENYZMES | GENENTECH INC (US) | 2008-02-27 | — | — | EP | disclosed |
| EP-1781287-A2 | THIAZOLE BASED INHIBITORS OF ATP-UTILIZING ENYZMES | Genentech, Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20060052416-A1 | 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof | SQUARE 1 BANK | 2006-03-09 | — | — | US | disclosed |
| WO-2006020767-A2 | THIAZOLE BASED INHIBITORS OF ATP-UTILIZING ENZYMES | GENENTECH, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048313-A1 | 2-AMIDO-THIAZOLE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | ATP5ME, ATP5MG, ATP5MK | KDM4E 3385/4885ALDH1A1 554/4885L3MBTL1 3981/4885 |
| US-20060052416-A1 | 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof | ATP5ME, ATP5MG, ATP5MK | KDM4E 3385/4885ALDH1A1 554/4885L3MBTL1 3981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.